Invivo Therapeutics Holdings Corp (OTC:NVIV) has been on the progressive move over the past days. Yesterday, the stock 
soared another 23.56% on a substantially high traded volume. What’s next today
Apparently, Invivo relies on fresh news to pump up its stock price as the announcements have been coming up regularly lately. The latest ones reported the company’s presentation at the Annual Piper Jaffray Health Care Conference and a research report on NVIV, which additionally provoked investors’ interest.
Following the records, the news supported by stock alerts are the usual PR strategy of Invivo. Only a week ago, NVIV hit the gain on promotions again, however, soon the climb was broken.
InVivo Therapeutics Corporation is developing and intends to commercialize groundbreaking technologies for the treatment of spinal cord injuries. Despite of the company’s optimistic statements, its latest 10-Q was completely discouraging.[BANNER]
The huge expenses, enormous operating loss and the shocking deficit accumulated during the development stage period could easily be seen. At the same time, the company’s cash position is not able to cover any of these, while NVIV keeps waiting for an FDA approval for its second product.
The management believes that its cash will fund the operations through March 31, 2012. However, the team claims that Invivo will need to raise substantial additional capital to complete its projects.
